Background {#Sec1}
==========

In 2014, the global prevalence of diabetes mellitus (DM) was estimated to be 9 % among adults aged over 18 years \[[@CR1]\] reaching epidemic rates in the 21st century \[[@CR2]\]. The number of patients diagnosed with DM is continuously increasing due to the increasing prevalence of hyperlipidaemia, visceral obesity and physical inactivity worldwide \[[@CR2]--[@CR4]\]. The total number of people suffering from DM is projected to rise to 552 million in 2030 \[[@CR5]\].

Regular consumption of complex preparations containing various vitamins, minerals, and trace elements (MVT) is common in developed countries \[[@CR6]\] to maintain general health. In the USA, for instance, more than half of the adult population use dietary supplements \[[@CR7], [@CR8]\], primarily in the form of multivitamins with or without minerals \[[@CR9], [@CR10]\]. In 1998 a study reported that in Germany 18 % of men and 25 % of women were regular consumers of multivitamins among 18--79 years old adults \[[@CR11]\]. Moreover, MVT preparations appeared on the market as medical food for patients suffering from metabolic diseases including hyperlipidaemia, metabolic syndrome, and DM. However, the literature is limited and controversial on the potential beneficial effects of these complex preparations containing more than 3 components on disease progression \[[@CR12]--[@CR16]\]. We have recently shown that chronic treatment with a MVT preparation improved well-established diagnostic markers of DM such as fasting blood glucose, HbA1c, glucose tolerance, and serum insulin levels in male diabetic rats \[[@CR14]\].

It is well known that diabetic patients have an increased risk of developing cardiovascular diseases including diabetic cardiomyopathy \[[@CR17]\]. Cardiovascular complications are estimated to be responsible for more than 50 % of deaths among this population \[[@CR18]\]. To explain the development of cardiovascular complications, the effect of DM on the cardiac gene expression pattern was investigated in a few studies \[[@CR19]--[@CR22]\]. In addition, we have previously shown that metabolic syndrome, which is a precursor state of type 2 DM, alters cardiac gene expression pattern in male ZDF rats \[[@CR23]\]. However, the effect of MVT preparations on the cardiac gene expression pattern either in healthy or in diabetic condition has not yet been investigated.

Therefore, here we aimed at investigating the effects of a MVT preparation containing 26 different minerals, vitamins and vitamin-like antioxidants, as well as trace elements on the cardiac gene expression pattern in male diabetic rats.

Materials and methods {#Sec2}
=====================

Animals {#Sec3}
-------

This investigation conforms to the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Pub. No. 85--23, Revised 1996) and was approved by the Animal Research Ethics Committee of the University of Szeged.

Two-day old neonatal male Wistar rats were used in this study. Lactating females with their litters were separately housed in individually ventilated cages (Sealsafe IVC system, Italy) and were maintained in a temperature-controlled room using 12:12 h light:dark cycles for 4 weeks. After separation from the mother at week 4, males were fed with standard rat chow (Additional file [1](#MOESM1){ref-type="media"}) and housed in pairs under the same circumstances as mentioned above until 12 weeks of age.

The injection of neonatal rats with streptozotocin (STZ) is a well characterized and recognized model of diabetes mellitus \[[@CR24]--[@CR27]\]. This model has been particularly characterized in detail in our previous study \[[@CR14]\]. STZ is toxic especially to pancreatic β-cells. In contrast to injection of STZ to adult rats in a lower dose (60 mg/kg) that leads to type 1 diabetes with severe hyperglycemia \[[@CR14], [@CR24]--[@CR27]\], administration of STZ to neonatal rats in a higher dose (90--100 mg/kg) leads to acute hyperglycemia within the first few days without resulting in complete loss of insulin production \[[@CR14], [@CR24]--[@CR27]\]. According to literature data, after 5--6 weeks, the surviving rats develop characteristic symptoms of type 2 diabetes mellitus including dyslipidemia, hyperglycemia, impaired glucose tolerance and insulin resistance due to decreased β-cell mass \[[@CR14], [@CR24]--[@CR27]\]. After 10--12 weeks, cardiovascular complications including hypertension and LV hypertrophy with decreased cardiac function are present in neonatal STZ-treated rats \[[@CR28]--[@CR34]\]. Therefore, this model is an appropriate choice to perform anti-diabetic drug screening studies.

Experimental protocol {#Sec4}
---------------------

Two days old neonatal male Wistar rats were intraperitoneally injected with 100 mg/kg of STZ (*n* = 25) or its vehicle (ice-cold citrate buffer, *n* = 16) to induce experimental DM as described earlier \[[@CR14]\].

At week 4, fasting blood glucose (FBG) measurement followed by an oral glucose tolerance test (OGTT) were performed in order to verify the development of impaired glucose tolerance in DM in surviving animals (data not shown). Mortality rates were 0 % and 36 % in citrate buffer-treated and in the STZ-treated group, respectively. Both citrate buffer-treated (*n* = 16) and STZ-treated rats (*n* = 16) were then supplemented per os via gavage (1 mL/kg, 1 % methylcellulose suspension) with a MVT preparation (253.3 mg/kg/day, suspended in methylcellulose, *n* = 8-8) or its vehicle (157 mg/kg/day, suspended in methylcellulose, *n* = 8-8) for 8 weeks as described previously \[[@CR14]\]. The MVT preparation administered in the present study is a registered medical food for human use (Diacomplex film-coated tablet, Béres Pharmaceuticals, Budapest, Hungary; for content see Table [1](#Tab1){ref-type="table"}). To conform to the human daily dose of the preparation, the daily rat dose was adjusted according to the ratio of human and rat body surface areas as described previously \[[@CR14]\]. Body weight was monitored every week. FBG, haemoglobin A1c level measurement and OGTT were performed at week 12 to assess the effect of MVT-treatment on DM. Serum insulin measurements were performed at week 4, 8 and 12 in order to monitor the insulin secretion of pancreatic beta cells and the effect of MVT-treatment on the severity of pancreatic beta cell damage due to STZ-treatment. At week 12, the rats were anaesthetized using pentobarbital (Euthasol, i.p. 50 mg/kg; Produlab Pharma b.v., Raamsdonksveer, The Netherlands) \[[@CR35]\]. Hearts and pancreata were isolated, and then the hearts were perfused according to Langendorff as described earlier \[[@CR36], [@CR37]\]. Coronary flow was measured during the ex vivo perfusion protocol \[[@CR35]\]. After 10 min perfusion, ventricular tissue was frozen and stored at −80 °C until DNA microarray investigation and gene expression analysis could be performed. Pancreata were removed, trimmed free of adipose tissue, then frozen and stored for pancreatic insulin content determination as described previously \[[@CR23]\].Table 1Ingredients of the MVT preparationActive ingredientsAmount of ingredient/1 g productDaily dose^a^Vitamin A~1~ (Retinol)329 μg/g (109700 IU/g)83.3 μg/kg/day (278 IU/kg/day)Vitamin B~1~ (Thiamin)2.30 mg/g0.58 mg/kg/dayVitamin B~2~ (Riboflavin)2.63 mg/g0.67 mg/kg/dayVitamin B~3~ (Nicotinamide)11.8 mg/g2.99 mg/kg/dayVitamin B~5~ (Pantothenic acid)3.95 mg/g1.00 mg/kg/dayVitamin B~6~ (Pyridoxine)3.29 mg/g0.83 mg/kg/dayVitamin B~12~ (Cyanocobalamin)3 μg/g0.76 μg/kg/dayFolic acid197 μg/g49.9 μg/kg/dayBiotin99 μg/g25.1 μg/kg/dayVitamin D~3~ (Cholecalciferol)3 μg/g (120 IU/g)0.76 μg/kg/day (30.4 IU/kg/day)Vitamin K~1~ (Phyllokinone)26 μg/g6.59 μg/kg/dayRutoside3.29 mg/g0.83 mg/kg/dayVitamin C65.8 mg/g16.7 mg/kg/dayVitamin E32.9 mg/g8.33 mg/kg/dayLutein1.97 mg/g0.50 mg/kg/dayChrome39 μg/g9.88 μg/kg/dayZinc9.87 mg/g2.50 mg/kg/daySelenium26 μg/g6.59 μg/kg/dayIron2.63 mg/g0.67 mg/kg/dayIodine66 μg/g16.7 μg/kg/dayManganese0.66 mg/g0.17 mg/kg/dayCopper921 μg/g233 μg/kg/dayMolybdenum49 μg/g12.4 μg/kg/dayMagnesium65.8 mg/g16.7 mg/kg/dayCalcium132 mg/g33.4 mg/kg/dayPhosphorus102 mg/g25.8 mg/kg/day^a^To conform to the human daily dose of the preparation, rat daily dose was adjusted according to the ratio of human and rat body surface areas

FBG measurements and OGTT {#Sec5}
-------------------------

Rats were fasted overnight (12 h) prior to blood glucose level measurement and OGTT (week 12) in order to verify the development of DM and to monitor the effect of MVT-treatment on the progression of DM as described previously \[[@CR14]\]. Briefly, blood samples were collected from the saphenous vein and blood glucose levels were measured using Accucheck blood glucose monitoring systems (Roche Diagnostics Corporation, USA, Indianapolis) \[[@CR14], [@CR23]\]. After measurement of baseline glucose concentrations, glucose at 1.5 g/kg body weight was administered via oral gavage and plasma glucose levels were measured 30, 60 and 120 minutes later during OGTT \[[@CR14], [@CR23]\].

Haemoglobin A1c measurement {#Sec6}
---------------------------

To monitor the effect of the MVT containing preparation on the severity of DM, haemoglobin A1c was measured from whole venous blood with an in vitro test (Bio-Rad in2it System) according to the instructions of the manufacturer \[[@CR14]\]. The test is based on single wave length photometry (440 nm) to detect glycated fraction separated from the non-glycated fraction by boronate affinity chromatography \[[@CR14]\].

Measurement of serum and pancreatic insulin levels {#Sec7}
--------------------------------------------------

To monitor the effect of MVT-treatment on the severity of DM, serum and pancreatic insulin levels were measured by an enzyme immunoassay (Mercodia, Ultrasensitive Rat Insulin ELISA) in duplicates according to the manufacturer's instructions as described previously \[[@CR14], [@CR23]\].

RNA preparation and DNA microarray analysis {#Sec8}
-------------------------------------------

Total RNA was isolated from heart samples with Qiagen miRNeasy Mini Kit according to the manufacturer's protocol (Qiagen, Hilden, Germany). On-column DNase digestion was carried out with the RNase-Free DNase Set (Qiagen GmbH). RNA concentration was measured by NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific Inc., Waltham, MA, USA) and RNA integrity was determined by an Agilent 2100 Bioanalyzer System (Agilent Technologies Inc., Santa Clara, CA, USA). Samples with an RNA integrity number (RIN) above 8.0 were used for further analysis. RNA was stored at −80 °C until use.

Total RNA (200 ng) was labelled and amplified using the Low Input Quick Amp Labelling Kit according to the instructions of the manufacturer. Labelled RNA was purified and hybridized to Agilent Whole Rat Genome 4x44K array slides, according to the manufacturer's protocol. After washing, array scanning and feature extraction was performed with default scenario by Agilent DNA Microarray Scanner and Feature Extraction Software 11.01.

Messenger RNA (mRNA) expression profiling by qRT-PCR {#Sec9}
----------------------------------------------------

In order to validate gene expression changes obtained by DNA microarray, qRT-PCR was performed on a RotorGene 3000 instrument (Corbett Research, Sydney, Australia) with gene-specific primers and SybrGreen protocol to monitor gene expression as described earlier \[[@CR23]\]. Briefly, 2 μg of total RNA was reverse transcribed using the High-Capacity cDNA Archive Kit (Applied Biosystems Foster City, CA, USA) according to the manufacturer's instructions in a final volume of 30 μL. After dilution with 30 μL of water, 1 μL of the diluted reaction mix was used as a template in the qRT-PCR with FastStart SYBR Green Master mix (Roche Applied Science, Mannheim, Germany) with the following protocol: 10 min at 95 °C followed by 45 cycles of 95 °C for 15 sec, 60 °C for 25 sec and 72 °C for 25 sec. The fluorescence intensity of SybrGreen dye was detected after each amplification step. Melting temperature analysis was done after each reaction to check the quality of the products. Primers were designed using the online Roche Universal Probe Library Assay Design Center. The quality of the primers was verified by MS analysis provided by Bioneer (Daejeon, Korea). Relative expression ratios were calculated as normalized ratios to rat HPRT and Cyclophyllin genes. A non-template control sample was used for each primer to check primer-dimer formation. The final relative gene expression ratios were calculated as delta-delta Ct values. Fold change refers to 2^-ΔΔCt^ (in the case of up-regulated genes) and --(1/2^-ΔΔCt^) (in the case of down-regulated genes).

Statistical analysis {#Sec10}
--------------------

Statistical analysis was performed by using Sigmaplot 12.0 for Windows (Systat Software Inc). All values are presented as mean ± SEM. Two-Way ANOVA was used to determine the effect of DM or MVT on body weight, FBG, glucose levels during OGTT, OGTT AUC, HbA1c, serum and pancreatic insulin concentrations, pancreas weight and coronary flow. After ANOVA, all pairwise multiple comparison procedures with *Holm-Šídák post hoc* tests were used as multiple range tests. *P* \< 0.05 was accepted as a statistically significant difference.

In the microarray experiments, biological and technical replica tests were carried out to gain raw data for statistical analysis. Altogether 9 individual parallel gene activity comparisons were done between two groups. Both in the microarray and qRT-PCR experiments, a two-sample *t*-test was used and the p value was determined to find significant gene expression changes in 3 separate comparisons. In the microarray experiments, a corrected p value was determined for each gene to control the false discovery rate using the *Benjamini and Hochberg* multiple testing correction protocol. Gene expression ratios with p value of \<0.05 and log~2~ ratio of \< −0.85 or log~2~ ratio of \>0.85 (\~1.8 fold change) were considered as repression or overexpression respectively in gene activity.

Results {#Sec11}
=======

Characterization of experimental DM and the effects of MVT-treatment on the progression of DM {#Sec12}
---------------------------------------------------------------------------------------------

The time dependence of development of DM in neonatal STZ-treated rats in both genders has been particularly characterized in detail in our previous study \[[@CR14]\]. In the present study, concentrations of several plasma metabolites and body weight were measured in order to verify the development of DM in the STZ-treated rats (Fig. [1](#Fig1){ref-type="fig"}). OGTT showed increased glucose levels at every time point following oral glucose load accompanied with increased area under the curve (AUC) values in STZ-treated groups showing impaired glucose tolerance (Fig. [1a and b](#Fig1){ref-type="fig"}). MVT-treatment significantly decreased glucose and OGTT AUC values in the STZ-treated groups, proving an anti-diabetic effect of the MVT preparation (Fig. [1a and b](#Fig1){ref-type="fig"}). FBG level was significantly higher in STZ-treated groups as compared to the control group showing the development of DM (Fig. [1c](#Fig1){ref-type="fig"}). However, FBG level was significantly decreased by MVT-treatment in the STZ-treated diabetic group (Fig. [1c](#Fig1){ref-type="fig"}). HbA1c level was significantly increased in STZ-treated groups as compared to controls (Fig. [1d](#Fig1){ref-type="fig"}) demonstrating chronic hyperglycaemia and the development of DM. Interestingly, MVT-treatment significantly reduced the HbA1c level in the STZ-treated diabetic group (Fig. [1d](#Fig1){ref-type="fig"}). Serum insulin levels were significantly decreased in the STZ-injected vehicle-treated group as compared to control vehicle-treated group both at week 4 (0.05 ± 0.01 vs. 0.16 ± 0.02 μg/mL) and 8 (0.08 ± 0.02 vs. 0.17 ± 0.02 μg/mL) proving deteriorated pancreatic beta cell function in DM. MVT-treatment had no significant effect on serum insulin levels at weeks 4 and 8 in diabetic (0.06 ± 0.01 and 0.12 ± 0.03 μg/mL, respectively) and control animals (0.12 ± 0.02 and 0.25 ± 0.03 μg/mL) when compared to appropriate vehicle-treated controls. At week 12, serum and pancreatic insulin concentration were significantly decreased in STZ-treated diabetic animals, proving pancreatic β-cell damage (Fig. [1e and f](#Fig1){ref-type="fig"}). MVT-treatment showed a significant increase in serum insulin concentrations in STZ-treated animals (Fig. [1e](#Fig1){ref-type="fig"}). However, MVT-treatment failed to significantly improve pancreatic insulin content in STZ-treated diabetic animals (Fig. [1f](#Fig1){ref-type="fig"}). In addition, body weight gain of STZ-treated rats was significantly lower as compared to control rats. However, weight gain was significantly improved by the MVT-treatment in the STZ-treated group (Fig. [1g](#Fig1){ref-type="fig"}). Neither DM nor MVT-treatment had a significant effect on pancreas weight (Fig. [1h](#Fig1){ref-type="fig"}). Coronary flow was significantly lower in the diabetic vehicle-treated group as compared to the control vehicle-treated group (16.4 ± 2.04 vs. 19.25 ± 0.48 mL/min) showing impaired cardiac function in diabetic hearts. However, MVT-treatment failed to improve coronary flow in the diabetic group (17.0 ± 0.52 mL/min) and had no significant effect in the control group either (19.29 ± 0.94 mL/min).Fig. 1*Characterization of experimental DM and the effects of MVT-treatment on the progression of DM.* **a** Blood glucose levels during oral glucose tolerance test (OGTT) and **b** its area under the curve (AUC). **c** Level of fasting blood glucose and **d** haemoglobin A1c. **e** Serum and **f** pancreas insulin. **g** Body and **h** pancreas weight. Values are expressed as mean ± S.E.M. *\*p* \< 0.05 vs. control, \#*p* \< 0.05 vs. diabetes vehicle, two-way ANOVA, n = 8 in each group. Cont = Control, Diab = Diabetes, Veh = Vehicle, MVT = preparation of minerals, vitamins, and trace elements

Global cardiac gene expression changes {#Sec13}
--------------------------------------

To determine genes in 1) diabetic vehicle-treated, 2) diabetic MVT-treated, 3) control vehicle-treated and 4) control MVT-treated groups, total RNA isolation and then DNA microarray analysis were performed from the hearts of all groups. Among the 41012 rat oligonucleotides surveyed, 16752 oligonucleotides in diabetic vehicle-treated group, 17531 oligonucleotides in diabetic MVT-treated group, 17447 oligonucleotides in control vehicle-treated group and 17184 oligonucleotides in control MVT-treated group showed expression.

Identification of genes associated with DM {#Sec14}
------------------------------------------

To determine genes associated with DM and diabetic cardiomyopathy, cardiac gene expression induced in the diabetic vehicle-treated group was compared with the control vehicle-treated group (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). In diabetic vehicle-treated hearts, 37 genes showed significant up-regulation and 22 genes showed significant down-regulation (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}).Table 2Genes significantly down-regulated in diabetes vehicle-treated vs. control vehicle-treated group on DNA microarrayDiabetes VehicleDiabetes MVTControl MVTvs.vs.vs.Control VehicleDiabetes VehicleControl VehicleGene functionGene Name *provided by RGD* ^*a*^Acc. Number*Gene Symbol*Log~2~ (SD)Corr. *p*Fold changeLog~2~ (SD)Fold ChangeLog~2~ (SD)Fold ChangeMetabolismUDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 2NM_001109492*B3galt2*-1.14 (0.19)0.003-2.210.80 (0.49)1.74-0.16 (0.60)-1.11Metabolismadenylate kinase 4NM_017135*Ak4*-0.99 (0.49)0.026-1.990.76 (0.40)1.70-0.47 (0.70)-1.38Stress responseAPEX (apurinic/apyrimidinic) endonuclease 2NM_001079892*Apex2*-0.94 (0.56)0.042-1.920.09 (0.26)1.06-1.18 (0.63)-2.26Apoptosis/necrosis and inflammationcaspase recruitment domain family, member 9NM_022303*Card9*-2.74 (0.64)0.003-6.691.82 (0.52)3.53-1.20^*b*^ (0.88)-2.29Apoptosis/necrosis and inflammationchemokine (C-X-C motif) ligand 12NM_001033883*Cxcl12*-0.86 (0.38)0.021-1.820.48 (0.40)1.400.06 (0.30)1.04Cell growth and differentiationneuronal regeneration related proteinNM_178096*Nrep*-1.11 (0.55)0.023-2.460.50 (0.49)1.41-1.46^*b*^ (1.36)-2.74Cell growth and differentiationHOP homeoboxNM_133621*Hopx*-1.14 (0.52)0.020-2.200.60 (0.49)1.51-0.28 (0.71)-1.21Cell growth and differentiationfibroblast growth factor 18NM_019199*Fgf18*-1.12 (0.53)0.021-2.170.80 (0.57)1.74-0.51 (0.23)-1.43Cell growth and differentiationret proto-oncogeneNM_012643*Ret*-1.04 (0.14)0.003-2.060.63 (0.39)1.55-0.63 (0.15)-1.55Cell growth and differentiationG0/G1 switch 2NM_001009632*G0s2*-0.86 (0.21)0.007-1.820.58 (0.47)1.500.26 (0.91)1.20Receptors and ion channelsadrenoceptor alpha 1DNM_024483*Adra1d*-1.21 (0.52)0.016-2.311.12 (0.40)2.17-1.03^*b*^ (1.36)-2.04Receptors and ion channelsFXYD domain-containing ion transport regulator 3NM_172317*Fxyd3*-1.01 (0.49)0.023-2.011.97 (0.48)3.92-0.36 (0.85)-1.29Receptors and ion channelssodium channel, voltage-gated, type IV, betaNM_001008880*Scn4b*-0.94 (0.30)0.011-1.920.38 (0.15)1.30-0.43 (0.49)-1.35Receptors and ion channelstransferrin receptorNM_022712*Tfrc*-0.87 (0.21)0.007-1.830.09 (0.20)1.06-0.55 (0.32)-1.46Structural protein, cell adhesionmyosin binding protein C, fast-typeNM_001106257*Mybpc2*-0.93 (0.47)0.026-1.900.33 (0.52)1.250.48 (0.82)1.40Structural protein, cell adhesionprotocadherin 17NM_001107279*Pcdh17*-0.94 (0.44)0.023-1.910.90 (0.43)1.86-0.65 (0.43)-1.57Hormonesinhibin alphaNM_012590*Inha*-0.89 (0.39)0.020-1.851.59 (0.79)3.010.66 (0.21)1.58Transportglobin, alphaNM_001013853*LOC287167*-1.64 (0.72)0.015-3.12-0.23 (0.81)-1.18-1.80 (0.76)-3.47Transporthaemoglobin, beta adult major chainNM_198776*Hbb-b1*-1.94 (0.75)0.011-3.83-0.40 (0.77)-1.32-2.23 (0.76)-4.71Transportalpha-2u globulin PGCL5NM_147213*LOC259245*-0.87 (0.54)0.047-1.83-0.03 (0.48)-1.02-0.12 (0.58)-1.08Othersuncharacterized LOC100909684XR_146107*LOC10099684*-3.07 (1.43)0.016-8.432.55 (1.40)5.85-0.42 (0.76)-1.34Othersuncharacterized LOC100910110XR_146304*LOC100910110*-1.94 (0.32)0.003-3.852.32 (0.31)5.01-0.46 (1.57)-1.38Values show gene expression. Log~2~ ratio reaching at least ±0.85 and *p* \< 0.05 were considered as significant alterations^a^RGD: rat genome database^b^non significant change (*p* \> 0.05)Table 3Genes significantly up-regulated in diabetes vehicle-treated vs. control vehicle-treated group on DNA microarrayDiabetes VehicleDiabetes MVTControl MVTvs.vs.vs.Control VehicleDiabetes VehicleControl VehicleGene functionGene Name *provided by RGD* ^*a*^Acc. Number*Gene Symbol*Log~2~ (SD)Corr. *p*Fold changeLog~2~ (SD)Fold ChangeLog~2~ (SD)Fold ChangeMetabolismUDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 15XM_003752864*Galnt15*0.85 (0.53)0.0471.81−0.58 (0.40)−1.490.32 (0.55)1.25Metabolismmicrotubule associated monooxygenase, calponin and LIM domain containing 1NM_001106397*Mical1*0.89 (0.23)0.0071.86−0.21 (0.19)−1.160.52 (0.23)1.43Metabolismproline dehydrogenase (oxidase) 1NM_001135778*Prodh*0.95 (0.48)0.0261.93−0.27 (0.63)−1.210.93 (0.50)1.91Metabolism4-hydroxyphenylpyruvate dioxygenaseNM_017233*Hpd*1.07 (0.38)0.0112.09−0.06 (0.34)−1.041.00 (0.48)2.01Stress responseglutathione S-transferase, theta 3NM_001137643*Gstt3*0.88 (0.52)0.0421.84−0.13 (0.38)−1.090.61 (0.80)1.52Stress responseheme oxygenase (decycling) 1NM_012580*Hmox1*1.08 (0.47)0.0172.12−0.62 (0.49)−1.540.52 (0.25)1.43Stress responsemetallothionein 1aNM_138826*Mt1a*1.32 (0.34)0.0052.49−1.18 (0.43)−2.260.09 (0.39)1.06Stress responsemetallothionein 2aNM_001137564*Mt2a*1.61 (0.34)0.0033.06−1.70 (0.66)−3.240.24 (0.53)1.18Immune responseNLR family member X1NM_001025010*Nlrx1*0.87 (0.48)0.0361.83−1.07 (0.43)−2.100.30 (0.43)1.23Immune responseFK506 binding protein 5NM_001012174*Fkbp5*1.13 (0.52)0.0202.19−1.09 (0.32)−2.130.83 (0.74)1.77Immune responseinfluenza virus NS1A binding proteinNM_001047085*Ivns1abp*1.27 (0.40)0.0082.41−0.65 (0.35)−1.570.68 (0.79)1.60Apoptosis/necrosis and inflammationinterleukin 6 receptorNM_017020*Il6r*0.91 (0.50)0.0341.88−1.00 (0.47)−2.000.63 (0.67)1.54Cell growth and differentiationH19, imprinted maternally expressed transcriptNR_027324*H19*0.92 (0.49)0.0321.89−0.53 (0.47)−1.441.16 (0.44)2.24Cell growth and differentiationsecreted frizzled-related protein 2NM_001100700*Sfrp2*1.22 (0.73)0.0392.34−0.62 (0.77)−1.540.87^*b*^ (0.73)1.83Cell growth and differentiationwingless-type MMTV integration site family, member 2BNM_001191848*Wnt2b*1.32 (0.11)0.0032.50−1.66 (0.48)−3.150.16 (0.11)1.11Cell growth and differentiationbrain expressed, X-linked 1NM_001037365*Bex1*1.41 (0.30)0.0032.65−1.97 (0.45)−3.920.25 (0.81)1.19Cell growth and differentiationN-myc downstream regulated 1NM_001011991*Ndrg1*0.85 (0.42)0.0271.81−1.05 (0.33)−2.070.41 (0.62)1.33Receptors and ion channelssolute carrier family 26 (anion exchanger), member 3NM_053755*Slc26a3*0.88 (0.34)0.0151.84−0.03 (0.23)−1.020.01 (0.32)1.01Receptors and ion channelsATPase, H^+^ transporting, lysosomal V1 subunit G2NM_212490*Atp6v1g2*0.92 (0.41)0.0201.89−1.05 (0.43)−2.06−0.75 (0.22)−1.68Receptors and ion channelsATP-binding cassette, subfamily A (ABC1), member 1NM_178095*Abca1*1.01 (0.35)0.0112.01−0.22 (0.39)−1.170.54 (0.40)1.45Receptors and ion channelssarcolipinNM_001013247*Sln*1.07 (0.61)0.0362.10−0.23 (0.42)−1.171.09 (0.61)2.13Signal transduction, regulation of transcriptionzinc finger and BTB domain containing 16NM_001013181*Zbtb16*0.89 (0.29)0.0111.85−0.69 (0.33)−1.620.37 (0.52)1.30Signal transduction, regulation of transcriptionRho-related BTB domain containing 1NM_001107622*Rhobtb1*0.91 (0.25)0.0081.88−0.22 (0.25)−1.160.58 (0.55)1.49Signal transduction, regulation of transcriptionconnector enhancer of kinase suppressor of Ras 1NM_001039011*Cnksr1*1.31 (0.67)0.0252.48−1.64 (0.38)−3.130.39 (0.72)1.31Signal transduction, regulation of transcriptioncytochrome P450, family 26, subfamily b, polypeptide 1NM_181087*Cyp26b1*1.62 (0.28)0.0033.08−1.68 (0.47)−3.200.25 (0.30)1.19Structural protein, cell adhesionpannexin 2NM_199409*Panx2*0.97 (0.17)0.0031.96−0.56 (0.33)−1.470.81 (0.15)1.75Structural protein, cell adhesionmyosin light chain kinase 2NM_057209*Mylk2*1.17 (0.32)0.0062.25−0.05 (0.37)−1.031.05^*b*^ (0.69)2.08HormonesresistinNM_144741*Retn*1.08 (0.60)0.0342.12−1.03 (0.44)−2.050.51 (0.96)1.43Hormonesgalanin/GMAP prepropeptideNM_033237*Gal*2.41 (1.15)0.0185.31−2.99 (0.92)−7.961.82^*b*^ (1.20)3.53Hormonesnatriuretic peptide ANM_012612*Nppa*1.23 (0.45)0.0112.34−0.62 (0.42)−1.540.79 (0.38)1.73Othersmyosin binding protein H-likeNM_001014042*Mybphl*1.26 (0.75)0.0382.39−0.66 (0.68)−1.581.09^*b*^ (0.71)2.13Othersprostaglandin D2 synthase (brain)NM_013015*Ptgds*1.32 (0.69)0.0262.50−0.64 (0.46)−1.560.67 (0.87)1.59Othersvisinin-like 1NM_012686*Vsnl1*1.49 (0.79)0.0262.80−1.01^*b*^ (0.77)−2.011.16^*b*^ (0.76)2.24Otherstransmembrane protein 140NM_001009709*Tmem140*1.49 (0.27)0.0032.80−0.59 (0.42)−1.500.30 (0.26)1.23OthersIQ motif and ubiquitin domain containingNM_001034130*Iqub*0.94 (0.36)0.0141.910.23 (0.20)420210.52 (0.59)1.44Otherssimilar to apolipoprotein L2; apolipoprotein L-IINM_001134801*RGD1309808*4.33 (2.91)0.04942358−6.07 (0.68)−67.241.61^*b*^ (3.76)3.05Othersthioredoxin domain containing 16XM_001072487*Txndc16*0.85 (0.31)0.0151.80−0.72 (0.32)−1.650.51 (0.32)1.42Values show gene expression. Log~2~ ratio reaching at least ±0.85 and *p* \< 0.05 were considered as significant alterations^a^RGD: rat genome database^b^non significant change (*p* \> 0.05)

Identification of genes associated with MVT-treatment in DM {#Sec15}
-----------------------------------------------------------

To determine genes associated with the effects of MVT-treatment in diabetic hearts, cardiac gene expression induced in the diabetic MVT-treated group was compared with the diabetic vehicle-treated group (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}). In diabetic MVT-treated hearts, 15 genes showed significant up-regulation and 29 genes showed significant down-regulation, compared to diabetic vehicle-treated controls (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}). In the diabetic MVT-treated group, an additional 23 genes were found, which expression pattern was significantly influenced only by the MVT-treatment. These 23 genes did not show significant gene expression change in the diabetic vehicle-treated group as compared to the control vehicle-treated group (Tables [2](#Tab2){ref-type="table"} and [5](#Tab5){ref-type="table"}). To assess potential beneficial effects of MVT-treatment, we analysed opposite gene expression changes in the diabetic MVT-treated group as compared to the diabetic vehicle-treated group. Among the oppositely altered genes in the diabetic MVT-treated group, 5 genes showed significant up-regulation and 14 genes showed significant down-regulation, respectively (Fig. [2](#Fig2){ref-type="fig"}). These 19 genes may be associated with potential cardioprotective effects of MVT-treatment in DM.Table 4Genes significantly down-regulated in diabetes MVT-treated vs. diabetes vehicle-treated group on DNA microarrayDiabetes MVTDiabetes VehicleControl MVTvs.vs.vs.Diabetes VehicleControl VehicleControl VehicleGene functionGene Name *provided by RGD* ^*a*^Acc. Number*Gene Symbol*Log~2~ (SD)Corr. *p*Fold changeLog~2~ (SD)Fold ChangeLog~2~ (SD)Fold ChangeMetabolismdipeptidase 1 (renal)L07315*Dpep1*−1.02 (0.27)0.007−2.030.79 (0.47)1.72−0.17 (0.50)−1.12Metabolismglycosylphosphatidylinositol anchored high density lipoprotein binding protein 1NM_001130547*Gpihbp1*−0.89 (0.18)0.006−1.860.59 (0.33)1.500.10 (0.37)1.07Metabolismflavin containing monooxygenase 2NM_144737*Fmo2*−0.85 (0.36)0.028−1.800.80 (0.24)1.740.12 (0.29)1.08Stress responsemetallothionein 2aNM_001137564*Mt2a*−1.70 (0.66)0.018−3.241.61 (0.34)3.060.24 (0.53)1.18Stress responsemetallothionein 1aNM_138826*Mt1a*−1.18 (0.43)0.017−2.261.32 (0.34)2.490.09 (0.39)1.06Immune responseFK506 binding protein 5NM_001012174*Fkbp5*−1.09 (0.32)0.008−2.131.13 (0.52)2.190.83 (0.74)1.77Immune responseNLR family member X1NM_001025010*Nlrx1*−1.07 (0.43)0.023−2.100.87 (0.48)1.830.30 (0.43)1.23Apoptosis/necrosis and inflammationchemokine (C-X-C motif) ligand 13NM_001017496*Cxcl13*−1.66 (0.84)0.036−3.170.61 (1.02)1.530.18 (0.96)1.14Apoptosis/necrosis and inflammationinterleukin 6 receptorNM_017020*Il6r*−1.00 (0.47)0.033−2.000.91 (0.50)1.880.63 (0.67)1.54Cell growth and differentiationbrain expressed, X-linked 1NM_001037365*Bex1*−1.97 (0.45)0.004−3.921.41 (0.30)2.650.25 (0.81)1.19Cell growth and differentiationwingless-type MMTV integrationsite family, member 2BNM_001191848*Wnt2b*−1.66 (0.48)0.007−3.151.32 (0.11)2.500.16 (0.11)1.11Cell growth and differentiationRAB3 GTPase activating protein subunit 2AI072072*Rab3gap2*−1.25 (0.57)0.029−2.380.53 (0.33)1.450.22 (0.53)1.17Cell growth and differentiationN-myc downstream regulated 1NM_001011991*Ndrg1*−1.05 (0.33)0.012−2.070.85 (0.42)1.810.41 (0.62)1.33Cell growth and differentiationWNT1 inducible signaling pathway protein 2NM_031590*Wisp2*−1.02 (0.53)0.043−2.020.60 (0.40)1.520.47 (0.34)1.39Cell growth and differentiationserine (or cysteine) peptidase inhibitor, clade A, member 3 NNM_031531*Serpina3n*−0.90 (0.48)0.048−1.87−0.03 (0.39)−1.020.90 (1.09)1.87Receptors and ion channelsATPase, H^+^ transporting,lysosomal V1 subunit G2NM_212490*Atp6v1g2*−1.05 (0.43)0.024−2.060.92 (0.41)1.89−0.75 (0.22)−1.68Receptors and ion channelsmelanocortin 2 receptoraccessory proteinNM_001135834*Mrap*−0.92 (0.42)0.033−1.890.65 (0.19)1.560.12 (0.21)1.09Signal transduction, regulation of transcriptioncytochrome P450, family 26, subfamily b, polypeptide 1NM_181087*Cyp26b1*−1.68 (0.47)0.007−3.201.62 (0.28)3.080.25 (0.30)1.19Signal transduction, regulation of transcriptionconnector enhancer of kinase suppressor of Ras 1NM_001039011*Cnksr1*−1.64 (0.38)0.004−3.131.31 (0.67)2.480.39 (0.72)1.31Structural protein, cell adhesionsolute carrier family 43 (amino acid system L transporter), member 2NM_001105812*Slc43a2*−1.06 (0.39)0.019−2.090.34 (0.19)1.27−0.07 (0.18)−1.05Hormonesgalanin/GMAP prepropeptideNM_033237*Gal*−2.99 (0.92)0.007−7.962.41 (1.15)5.311.82 (1.20)3.53HormonesresistinNM_144741*Retn*−1.03 (0.44)0.025−2.051.08 (0.60)2.120.51 (0.96)1.43Otherssimilar to apolipoprotein L2; apolipoprotein L-IINM_001134801*RGD1309808*−6.07 (0.68)\<0.001−67.244.33 (2.91)20.121.61 (3.76)3.05Otherssecreted phosphoprotein 1NM_012881*Spp1*−1.35 (0.59)0.025−2.55−0.40 (0.77)−1.322.30 (1.49)4.93Otherselongation of very long chain fatty acids protein 6-likeXM_003749393*LOC100910695*−1.01 (0.39)0.021−2.020.33 (0.43)1.25−0.94 (0.55)−1.92OthersWW domain binding protein 5NM_001127502*Wbp5*−0.99 (0.20)0.005−1.990.54 (0.15)1.450.07 (0.38)1.05Otherscoiled-coil domain containing 136XM_001064000*Ccdc136*−0.98 (0.10)0.002−1.980.62 (0.18)1.530.09 (0.39)1.06Othersmultimerin 1XM_001071128*Mmrn1*−0.91 (0.38)0.027−1.88−0.31 (0.36)−1.24−0.14 (0.31)−1.10Othersepsin 3NM_001024791*Epn3*−0.87 (0.44)0.043−1.820.46 (0.50)1.37−0.16 (0.32)−1.12Values show gene expression. Log~2~ ratio reaching at least ±0.85 and *p* \< 0.05 were considered as significant alterations^a^RGD: rat genome database^b^non significant change (*p* \> 0.05)Table 5Genes significantly up-regulated in diabetes MVT-treated vs. diabetes vehicle-treated group on DNA microarrayDiabetes MVTDiabetes VehicleControl MVTvs.vs.vs.Diabetes VehicleControl VehicleControl VehicleGene functionGene Name *provided by RGD* ^*a*^Acc. Number*Gene Symbol*Log~2~ (SD)Corr. *p*Fold changeLog~2~ (SD)Fold ChangeLog~2~ (SD)Fold ChangeMetabolismL-2-hydroxyglutarate dehydrogenaseNM_001108028*L2hgdh*1.06 (0.49)0.0322.09−0.52 (1.01)−1.440.04 (0.92)1.03Apoptosis/necrosis and inflammationchemokine (C-X-C motif) ligand 9NM_145672*Cxcl9*1.03 (0.40)0.0212.04−0.29 (0.60)−1.22−0.19 (0.81)−1.14Apoptosis/necrosis and inflammationcaspase recruitment domain family, member 9NM_022303*Card9*1.82 (0.52)0.0073.53−2.74 (0.64)−6.69−1.20^*b*^ (0.88)−2.29Receptors and ion channelsadrenoceptor alpha 1DNM_024483*Adra1d*1.12 (0.40)0.0172.17−1.21 (0.52)−2.31−1.03^*b*^ (1.36)−2.04Receptors and ion chanellsFXYD domain-containing ion transport regulator 3NM_172317*Fxyd3*1.97 (0.48)0.0043.92−1.01 (0.49)−2.01−0.36 (0.85)−1.29Signal transduction, regulation of transcriptionregulator of telomere elongation helicase 1NM_001191857*Rtel1*1.14 (0.27)0.0062.20−0.71 (1.02)−1.640.58 (1.14)1.49Signal transduction, regulation of transcriptionstaufen double-stranded RNA binding protein 2NM_001007149*Stau2*1.36 (0.71)0.0422.56−0.38 (0.27)−1.300.22 (0.41)1.16Structural protein, cell adhesionprotocadherin 17NM_001107279*Pcdh17*0.90 (0.43)0.0361.86−0.94 (0.44)−1.91−0.65 (0.43)−1.57Hormonesinhibin alphaNM_012590*Inha*1.59 (0.79)0.0353.01−0.89 (0.39)−1.850.66 (0.21)1.58Otherssimilar to HTGN29 protein; keratinocytes associated transmembrane protein 2NM_001106999*RGD131352*1.05 (0.48)0.0322.070.29 (0.49)1.230.49 (0.53)1.41OthersWDNM1 homologNM_001003706*LOC360228*1.32 (0.63)0.0332.50−0.59 (0.77)−1.501.01^*b*^ (0.67)2.01Othersring finger protein 135NM_001012010*Rnf135*0.86 (0.33)0.0231.82−0.44 (0.08)−1.35−0.06 (0.46)−1.05Othersuncharacterized LOC100910110XR_146304*LOC100910110*2.32 (0.31)0.0015.01−1.94 (0.32)−3.85−0.46 (1.57)−1.38Othersuncharacterized LOC100909684XR_146107*LOC10099684*2.55 (1.40)0.0455.85−3.07 (1.43)−8.43−0.42 (0.76)−1.34Othersserine hydrolase-like 2NM_001130579*Serhl2*5.17 (0.48)\<0.00135.96−3.62^*b*^ (2.81)−12.31−3.45^*b*^ (2.82)−10.92Values show gene expression. Log~2~ ratio reaching at least ±0.85 and *p* \< 0.05 were considered as significant alterations^a^RGD: rat genome database^b^non significant change (*p* \> 0.05)Fig. 2*Genes with significantly and oppositely altered expression in diabetes vehicle-treated* vs. *diabetes MVT-treated group.* **a** Significantly *down-*regulated genes in diabetes vehicle-treated group vs. control vehicle-treated group which are *up-*regulated in diabetes MVT-treated group vs. diabetes vehicle treated-group. No significant change in control MVT-treated group vs. control vehicle-treated group. **b** Significantly *up-*regulated genes in diabetes vehicle-treated group vs. control vehicle-treated group which are *down-*regulated in diabetes MVT-treated group vs. diabetes vehicle-treated group. No significant change in control MVT-treated group vs. control vehicle-treated group. Values are expressed as mean ± S.E.M. Log~2~ ratio reaching at least ±0.85 (represented with dotted lines) and *p* \< 0.05 were considered as significant alterations

Identification of genes associated with MVT-treatment in healthy condition {#Sec16}
--------------------------------------------------------------------------

To determine genes associated with the effects of MVT-treatment in healthy control hearts, cardiac gene expression induced in the control MVT-treated group was compared with the control vehicle-treated group (Tables [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}). In control MVT-treated hearts, 18 genes showed significant up-regulation and 6 genes showed significant down-regulation (Tables [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}). Out of these significantly altered 24 genes, 18 genes were not significantly altered in diabetic MVT-treated rats. These 18 genes may be associated with potential beneficial effects of MVT-treatment in healthy or diseased conditions.Table 6Genes significantly down-regulated in control MVT-treated vs. control vehicle-treated group on DNA microarrayControl MVTDiabetes VehicleDiabetes MVTvs.vs.vs.Control VehicleControl VehicleDiabetes VehicleGene functionGene Name *provided by RGD* ^*a*^Acc. Number*Gene Symbol*Log~2~ (SD)Corr. *p*Fold changeLog~2~ (SD)Fold ChangeLog~2~ (SD)Fold ChangeStress responseAPEX (apurinic/apyrimidinic) endonuclease) 2NM_001079892*Apex2*−1.18 (0.63)0.043−2.26−0.94 (0.56)−1.920.09 (0.26)1.06Receptors and ion channelssodium leak channel, non-selectiveNM_153630*Nalcn*−0.85 (0.44)0.043−1.80−0.59 (0.36)−1.500.16 (0.41)1.12Signal transduction, regulation of transcriptiontriggering receptor expressed on myeloid cells 2NM_001106884*Trem2*−1.03 (0.40)0.021−2.05−0.21 (0.88)−1.15−0.98 (0.94)−1.98Transporthemoglobin, beta adult major chainNM_198776*Hbb-b1*−2.23 (0.76)0.016−4.71−1.94 (0.75)−3.83−0.40 (0.77)−1.32Transportglobin, alphaNM_001013853*LOC287167*−1.80 (0.76)0.020−3.47−1.64 (0.72)−3.12−0.23 (0.81)−1.18OthersEF-hand calcium binding domain 6XM_001077962*Efcab6*−1.66 (0.62)0.017−3.150.40 (0.99)1.32−1.36^*b*^ (1.38)−2.57Values show gene expression. Log~2~ ratio reaching at least ±0.85 and *p* \< 0.05 were considered as significant alterations^a^RGD: rat genome database^b^non significant change (*p* \> 0.05)Table 7Genes significantly up-regulated in control MVT-treated vs. control vehicle-treated group on DNA microarrayControl MVTDiabetes VehicleDiabetes MVTvs.vs.vs.Control VehicleControl VehicleDiabetes VehicleGene functionGene Name *provided by RGD* ^*a*^Acc. Number*Gene Symbol*Log~2~ (SD)Corr. *p*Fold changeLog~2~ (SD)Fold ChangeLog~2~ (SD)Fold ChangeMetabolismproline dehydrogenase (oxidase) 1NM_001135778*Prodh*0.93 (0.50)0.0431.910.95 (0.48)1.93−0.27 (0.63)−1.21Metabolismenolase 2, gamma, neuronalNM_139325*Eno2*1.00 (0.30)0.0172.000.98^*b*^ (0.85)1.97−1.32^*b*^ (1.12)−2.50Metabolism4-hydroxyphenylpyruvate dioxygenaseNM_017233*Hpd*1.00 (0.48)0.0342.011.07 (0.38)2.09−0.06 (0.34)−1.04Immune responsecomplement factor BNM_212466*Cfb*0.85 (0.32)0.0251.800.14 (0.34)1.100.22 (0.34)1.17Immune response2'-5' oligoadenylate synthetase 1ANM_138913*Oas1a*0.92 (0.33)0.0201.900.40 (0.28)1.32−0.43 (0.24)−1.35Immune response2-5 oligoadenylate synthetase 1BAF068268*Oas1b*1.04 (0.18)0.0152.06−0.52 (0.50)−1.440.11 (0.83)1.08Immune response2'-5' oligoadenylate synthetase 1INM_001009680*Oas1i*0.87 (0.24)0.0181.830.13 (0.31)1.09−0.29 (0.22)−1.22Immune responseinterferon regulatory factor 7NM_001033691*Irf7*1.13 (0.27)0.0162.18−0.05 (0.12)−1.040.25 (0.20)1.19Immune responsecomplement component 4A (Rodgers blood group)NM_031504*C4a*1.18 (0.39)0.0172.270.29 (0.44)2.270.05 (0.34)1.04Immune responsehepcidin antimicrobial peptideNM_053469*Hamp*1.38 (0.74)0.0402.600.59 (0.77)1.51−0.56 (0.74)−1.47Immune responsemyxovirus (influenza virus) resistance 2NM_134350*Mx2*2.14 (0.95)0.0204.410.42 (0.63)1.34−0.72 (0.67)−1.65Cell growth and differentiationneuronatinNM_053601*Nnat*0.99 (0.41)0.0251.980.73 (0.40)1.66−0.06 (0.74)−1.04Cell growth and differentiationH19, imprinted maternally expressed transcriptNR_027324*H19*1.16 (0.44)0.0202.240.92 (0.49)1.89−0.53 (0.47)−1.44Receptors and ion channelsATPase, H^+^/K^+^ exchanging, alpha polypeptideNM_012509*Atp4a*0.86 (0.19)0.0171.810.45 (0.48)1.37−0.05 (0.59)−1.04Receptors and ion channelssarcolipinNM_001013247*Sln*1.09 (0.61)0.0432.131.07 (0.61)2.10−0.23 (0.42)−1.17Receptors and ion channelsATPase, Na^+^/K^+^ transporting, beta 4 polypeptideNM_053381*Atp1b4*1.14 (0.63)0.0432.210.41 (0.64)1.330.04 (0.81)1.03Others2'-5' oligoadenylate synthetase-like 2NM_001009682*Oasl2*0.96 (0.34)0.0201.95−0.21 (0.19)−1.150.08 (0.14)1.05OthersGRAM domain containing 3NM_001014011*Gramd3*0.97 (0.31)0.0181.96−0.03 (0.41)−1.020.36 (0.79)1.29Values show gene expression. Log~2~ ratio reaching at least ±0.85 and *p* \< 0.05 were considered as significant alterations^a^RGD: rat genome database^b^non significant change (*p* \> 0.05)

Validation of microarray data by qRT-PCR {#Sec17}
----------------------------------------

To confirm the microarray data we measured the expression of selected 5 genes by qRT-PCR in 2 different setups: 1) diabetes vehicle-treatment vs. control vehicle-treatment groups and 2) diabetes MVT-treatment vs. diabetes vehicle-treatment groups (Tables [8](#Tab8){ref-type="table"} and [9](#Tab9){ref-type="table"}). In both setups, the expression changes of 4 genes were confirmed by qRT-PCR and showed reliability of the microarray data.Table 8Primers to qRT-PCRGene nameGene symbolAcc. NumberForwardLengthReverseLengthmetallothionein 1aMt1aNM_138826caccagatctcggaatggac20aggagcagcagctcttcttg20metallothionein 2aMt2aNM_001137564catggaccccaactgctc18aggtgcatttgcattgtttg20cytochrome P450, family 26, subfamily b, polypeptide 1Cyp26b1NM_181087acggcaaggagatgacca18gcataggctgcgaagatca19galanin prepropeptideGalNM_033237tggagtttctcagtttcttgcac23ggtgtggtctcaggactgct20connector enhancer of kinase suppressor of Ras 1Cnksr1NM_001039011tgtggctgggatctgtcac19tgctggtggtgtgaatttct20Table 9qRT-PCR resultsDiabetes Vehicle vs. Control VehicleDescriptionGene symbolAcc. NumberDNA MICROARRAYqRT-PCRconfirmedfold changep valuelog~2~ ratio (SD)fold changeregulationmetallothionein 1aMt1aNM_1388262.490.0052.36 (1.35)5.13up*yes*metallothionein 2aMt2aNM_0011375643.060.0032.36 (0.93)5.12up*yes*cytochrome P450, family 26, subfamily b, polypeptide 1Cyp26b2NM_1810873.080.0032.50 (0.85)5.65up*yes*galanin/GMAP prepropeptideGalNM_0332375.310.0182.69 (0.86)6.43up*yes*connector enhancer of kinase suppressor of Ras 1Cnksr2NM_0010390112.480.0250.002 (0.26)1.00no changenoDiabetes MVT vs. Diabetes VehicleDescriptionGene symbolAcc. NumberDNA MICROARRAYqRT-PCRconfirmedfold changep valuelog~2~ ratio (SD)fold changeregulationmetallothionein 1aMt1aNM_138826−2.260.017−1,44 (0.91)−2.71down*yes*metallothionein 2aMt2aNM_001137564−3.240.018−2.53 (0.68)−5.76down*yes*cytochrome P450, family 26, subfamily b, polypeptide 1Cyp26b2NM_181087−3.200.007−2.91 (0.32)−7.50down*yes*galanin/GMAP prepropeptideGalNM_033237−7.960.007−2.72 (0.64)−6.60down*yes*connector enhancer of kinase suppressor of Ras 1Cnksr2NM_001039011−3.130.004−0.11 (0.33)1.08no changenoMVT = preparation of minerals, vitamins, and trace elements

Discussion {#Sec18}
==========

In the present study we have confirmed that chronic treatment with a MVT preparation attenuated the progression of DM by improving diagnostic markers of DM including glucose tolerance, FBG, HbA1c, and serum insulin levels in male diabetic rats \[[@CR14]\]. We have shown here that the development of DM induces marked alterations in the cardiac gene expression pattern. This is the first demonstration that a MVT preparation significantly altered the myocardial \[[@CR38], [@CR39]\] gene expression pattern by altering transcript levels of several genes in both diabetic and healthy rats. The significantly altered genes can be classified into different clusters (e.g. metabolism; stress response; immune response; cell growth and differentiation; ion channels and receptors; signal transduction and regulation of transcription; structural proteins and cell adhesion; hormones; transport; etc.). Some of these genes are related to the development of diabetic cardiomyopathy (e.g. cardiac hypertrophy and fibrosis, stress response, hormones associated with insulin resistance, etc.). Moreover, some other genes without any definite function in the myocardium were also changed in response to DM or MVT-treatment.

Genes associated with diabetic cardiomyopathy {#Sec19}
---------------------------------------------

One of the major cardiovascular complications of DM is diabetic cardiomyopathy (DCM) \[[@CR40], [@CR41]\], which is defined as left ventricular dysfunction with hypertrophy and fibrosis in the absence of hypertension, coronary artery disease and valvular or congenital heart disease \[[@CR42]\]. The complex underlying molecular mechanisms of the above-mentioned functional and morphologic changes have been intensively investigated \[[@CR40]--[@CR42]\]. In our present study, we have shown altered expression of several genes related to cardiac hypertrophy and remodelling in accordance with the literature (e.g. down-regulation of *caspase recruitment domain family*, *member 9 (Card9)* \[[@CR43]\] and *adrenoceptor alpha 1d (adra1d)* \[[@CR44]\]; up-regulation of the angiogenesis inductor *cytochrome P450, family 26, subfamily B, polypeptide 1 (Cyp26b1)* \[[@CR45], [@CR46]\]; *FXYD domain containing ion transport regulator 3 (Fxyd3)* also called phospholemman-like protein potentially regulating Na^+^/K^+^/ATP-ase activity \[[@CR47]--[@CR49]\]; *ATPase, H*^*+*^*Transporting, Lysosomal 13 kDa, V1 Subunit G21 (Atp6v1g2)* \[[@CR50]\] related to hepatitis C virus-associated dilated cardiomyopathy; and a well-known marker of hypertrophy and heart failure, *natriuretic peptide A* (Nppa) \[[@CR40], [@CR41]\] (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). In our present study, another group of genes altered in response to DM is involved in cell proliferation in different organs (e.g. down-regulation of the antiproliferative and tumour suppressor *protocadherin-17* (Pcdh17) \[[@CR51]\] and up-regulation of the insulin signalling pathway promoter *connector enhancer of kinase suppressor of Ras 1 (Cnksr1)* \[[@CR52], [@CR53]\]; *and wingless-type MMTV integration site family, member 2B (Wnt2b)* playing a role in pancreatic beta cell replication \[[@CR54]\] (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"})*.* These aforementioned studies, in agreement with our present study, suggest that altered metabolic parameters in DM may induce cardiac gene expression changes leading to the induction of general mechanisms of cell proliferation and cardiac hypertrophy. Nevertheless, these aforementioned genes have not previously been shown to play a role in the development of diabetic cardiomyopathy. In our present study, MVT-treatment in diabetic rats resulted in opposite gene expression changes in case of some aforementioned genes (e.g. *caspase recruitment domain family, member 9 (Card9); adrenoceptor alpha 1d (adra1d); cytochrome P450, family 26, subfamily B, polypeptide 1 (Cyp26b1; FXYD domain containing ion transport regulator 3 (Fxyd3); ATPase, H*^*+*^*Transporting, Lysosomal 13 kDa, V1 Subunit G21 (Atp6v1g2);* etc.) showing a beneficial effect of MVT-treatment on the development of diabetic cardiomyopathy (Tables [2](#Tab2){ref-type="table"} and [5](#Tab5){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}). Although we have not characterized diabetic cardiomyopathy in our present study, STZ-treated rats are well known to develop this cardiovascular complication at ages similar to that of used in the present study \[[@CR19]\].

Genes associated with increased oxidative/nitrative stress in DM {#Sec20}
----------------------------------------------------------------

Increased cardiovascular oxidative and nitrative stress is another well-known factor in the development of diabetic cardiomyopathy \[[@CR40], [@CR41]\]. In the present study, members of another functional gene cluster related to oxidative/nitrative stress and stress response showed altered expression in diabetic vehicle-treated hearts as compared to controls, in accordance with literature data (e.g. up-regulation of the zinc ion containing antioxidative *metallothionein 1a (Mt1a)* and *metallothionein 2a (Mt2a*) \[[@CR55], [@CR56]\]; the cardiovascular risk factor *interleukin-6 receptor (Ilr6)* \[[@CR57], [@CR58]\]; the antioxidative *heme oxygenase (decycling) 1 (Hmox1)* \[[@CR59]\]; and *glutathione S-transferase, theta 3 (Gstt3)* \[[@CR60]\]) (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). Glutathione S-transferase catalyzes the conjugation of reduced glutathione on a wide variety of substrates \[[@CR60]\] including reactive oxygen and nitrogen species \[[@CR61]\]. Interestingly, we have found here the overexpression of glutathione S-transferase in DM similar to the up-regulation of this gene in metabolic syndrome \[[@CR23]\] and cholesterol diet-induced hyperlipidaemia \[[@CR62]\] in our previous studies. Our results suggest that up-regulation of antioxidative genes including *glutathione S-transferase; heme oxygenase 1; metallothionein 1a* and *2a* may be an adaptive response in DM to antagonize elevated oxidative/nitrative stress in the myocardium. In contrast, decreased expression of metallothionein proteins have been reported in the heart \[[@CR63]\] and the aorta \[[@CR64]\] in experimental diabetes. Moreover, it has been published that the expression of metallothioneins could be increased by a chelator-regulated restoration of copper regulation \[[@CR63]\] and zinc supplementation in experimental diabetes \[[@CR64], [@CR65]\]. Nevertheless, it should be noted that these aforementioned studies used different types of diabetes models (a genetic T1DM model OVE26 mice and single injection of STZ in adult mice or rats) with more severe hyperglycaemia than that developed in our model in the present study. In addition, we have previously shown marked differences in gene expression profiles in vascular and cardiac tissues in response to nitrate tolerance, which indicates different tissue-specific signalling pathways in different organs \[[@CR66]\]. MVT-treatment in diabetic rats showed opposite gene expression changes in the cases of the aforementioned genes (Tables [2](#Tab2){ref-type="table"} and [5](#Tab5){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}). This could be explained by the beneficial effect of MVT-treatment on the severity of DM and potentially reduced oxidative/nitrative stress.

Genes associated with insulin resistance {#Sec21}
----------------------------------------

Insulin resistance is another well-known phenomenon in diabetic cardiomyopathy \[[@CR40], [@CR41]\]. Although the precise mechanisms by which cardiac insulin resistance developed in DM are poorly characterized, numerous metabolic and hormonal changes in the diabetic heart have been demonstrated \[[@CR19]--[@CR22], [@CR40], [@CR41]\]. In this present study, we have shown altered expression of several genes related to insulin resistance in the hearts of diabetic rats (e.g. up-regulation of *resistin (Retn)* responsible for induction of cardiac insulin resistance in rodents and chronic inflammation in humans \[[@CR67]\] and *FK506 binding protein 5 (Fkbp5)* associated with decreased ligand sensitivity of the glucocorticoid receptor \[[@CR68]\]. Interestingly, here we have shown up-regulation of *galanin/GMAP prepropeptide (Gal)* which has trophic effects on cells and increases insulin sensitivity in the diabetic heart \[[@CR69]\]. Increased expression of galanin might be a counter-regulatory mechanism against insulin resistance in the diabetic heart. Surprisingly, a regulatory hormone of the reproductive function, *inhibin 1-alpha (Inha)* \[[@CR70]\] showed significant up-regulation in the present study. Association of this gene with heart or DM has never been shown previously.

Genes not associated with DM before {#Sec22}
-----------------------------------

Some of the genes showing altered expression in diabetic hearts in the present study have not yet been related to diabetic cardiomyopathy (e.g. up-regulation of *prostaglandin b2 synthase (brain) (Ptgds); fibroblast growth factor (Fgf18)* and down-regulation *of HOP homeobox (Hopx); neuronal regeneration related protein (Nrep);* etc.*).* Interestingly, we have found here the overexpression of *brain expressed X-linked 1 (Bex1)* in DM similar to the up-regulation of this gene in metabolic syndrome \[[@CR23]\] in our previous study. Some other altered genes were not classified into specific functional clusters or indicated as yet uncharacterized, predicted genes and fragments (e.g. up-regulation of *RGD1309808* also called *similar to apolipoprotein L2* or down-regulation of *uncharacterized LOC100909684* and *LOC100910110* genes*)*, the relevance of which should not be ignored.

Genes altered in healthy condition due to MVT-treatment {#Sec23}
-------------------------------------------------------

Regular consumption of MVT preparations as medical food for diabetics is common in developed countries. However, preclinical or clinical evaluation of such preparations is surprisingly limited in the literature \[[@CR12]--[@CR16]\]. To the best of our knowledge, none of the investigated and significantly altered genes in this study has been reported to show altered expression, either in healthy or in diabetic hearts in response to MVT-treatment. In the present study, 24 genes showed significant alteration in control MVT-treated hearts as compared to control vehicle-treated hearts (Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}), however, we did not observe any phenotypic changes in this group. Out of the 24 aforementioned genes, 18 were not significantly altered in diabetic MVT-treated rats compared to the diabetes vehicle-treated ones; therefore, these genes might be associated to the beneficial effects of MVT-treatment observed in the diabetic group. Accordingly, a major cluster of significantly altered cardiac genes in response to MVT treatment in control animals was associated with immune and antimicrobial response (e.g. *complement factor B (Cfb); complement component 4a (C4a); interferon regulatory factor 7 (irf7)*; *hepcidin antimicrobial peptide (Hamp)*; *myxovirus (influenza virus) resistance 2 (Mx2)*; and viral RNA degradation regulators including *2′-5′′ oligoadenylate synthetase 1A; 1B; and 1 L;* as well as *2′-5′ oligoadenylate synthetase-like 2*) which is in line with the known immune system boosting effect of some of the components of the MVT preparation such as e.g. selenium \[[@CR71]\].

Limitations {#Sec24}
-----------

Our study is not without limitations. Based on our present results one may not be able to differentiate entirely between the effects of diabetes and postnatal development due to insulin insufficiency, however, this model may also have clinical significance in DM in the pediatric age \[[@CR72]\]. Furthermore, cardiac morphological and functional parameters to verify the development of diabetic cardiomyopathy were not investigated in this study; however, the neonatal STZ-injected rat is a well-characterized model of diabetes with cardiovascular complications including hypertension and LV hypertrophy with decreased cardiac function at a similar age to that used in our present study \[[@CR28]--[@CR34]\]. Although our study does not specify which cell type (i.e. cardiomyocyte, fibroblast, smooth muscle cell, etc.) may be responsible for the observed alterations of cardiac gene expression due to DM, the contribution of cardiomyocytes is likely the most significant \[[@CR38], [@CR39]\]. Although longer ex vivo heart perfusion was reported to alter cardiac gene expression profile \[[@CR73]\], it is unlikely that 10 min perfusion in our present study significantly affected gene expression profile, however, it still cannot be completely excluded that the stability of transcripts might have been influenced differentially by the crystalloid buffer used during ex vivo heart perfusion.

Our results regarding altered cardiac gene expression due to DM are based on determinations of 41012 cardiac transcript levels. Examination of the role of corresponding proteins was out of the scope of the present study; however, mechanistic data would strengthen our results. In addition, it is unclear whether significantly altered gene expression changes are causes or consequences in the development of diabetic cardiomyopathy. Moreover, it also needs to be further investigated whether the MVT-treatment in DM associated with opposite cardiac gene expression changes is the cause of attenuation of the severity of DM or a consequence of DM. Therefore, focused future studies are necessary to perform in-depth functional assessment of selected genes and specifically aim to investigate the precise role of these genes in the cardiac effects of diabetes mellitus and/or MVT-treatment. The results of the present study do not provide evidence on the mechanism of the MVT preparation and the different contributions of the 26 individual components. We assume that the potential interactions of these components and their combined effects rather than the value of a single component could be responsible for the effects of the MVT preparation on cardiac gene expression changes and the severity of DM; however, the effects of each component on gene expression or DM were not investigated in the present study. Indeed, a recent report \[[@CR74]\] showing a reduction of cancer risk in humans by a daily intake of multivitamins and minerals suggests that the combined effect of multivitamins is more important in the beneficial effect than any single component.

Conclusions {#Sec25}
===========

In summary, we have found that 12 week-old STZ-treated rats developed DM characterized by hyperglycaemia and impaired glucose tolerance. We have shown that the severity of DM could be attenuated by a complex MVT preparation. We have demonstrated for the first time that MVT-treatment is associated with profound modifications of the cardiac transcriptome in both healthy and diabetic conditions. In addition, several of the genes showing altered expression in the hearts of diabetic rats have not been implicated in DM previously. We conclude that DM alters the gene expression pattern of the myocardium, which may be involved in the development of cardiac pathologies in the state of DM and these pathological processes may be attenuated by MVT-treatment. Based on our exploratory results, future preclinical and clinical studies should be carried out to investigate the precise role of specific genes in the development of cardiac consequences of DM and MVT-treatment to obtain deeper mechanistic insight.

Additional file {#Sec26}
===============

Additional file 1:**Ingredients of the standard rat chow.**
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